Addressing Unmet Needs in Myelofibrosis

Slides:



Advertisements
Similar presentations
An overview of the differences of different JAK inhibitors
Advertisements

Ongoing clinical trials with JAK2 inhibitors in MF
Srdan (Serge) Verstovsek M.D., Ph.D. Professor of Medicine Department of Leukemia University of Texas MD Anderson Cancer Center Houston, Texas, USA JAK.
Srdan (Serge) Verstovsek M.D., Ph.D. Professor of Medicine Department of Leukemia University of Texas MD Anderson Cancer Center Houston, Texas, USA Therapy.
Results of a Randomized Study of the JAK Inhibitor Ruxolitinib (INC424) versus Best Available Therapy (BAT) in Primary Myelofibrosis (PMF), Post- Polycythemia.
Benefits of JAK2 Inhibitor Therapy: Why Do They Work in Patients With and Without JAK2 Mutation Alessandro M. Vannucchi Section of Hematology, University.
Results of a Phase II Study of Pacritinib (SB1518), a Novel Oral JAK2 Inhibitor, in Patients with Primary, Post-Polycythemia Vera, and Post- Essential.
Phase 2 Trial of PRM-151, an Anti-Fibrotic Agent, in Patients with Myelofibrosis: Stage 1 Results1 Imetelstat, a Telomerase Inhibitor, Therapy for Myelofibrosis:
Risk Stratification of Patients with Myelofibrosis and the Role of Transplant Alessandro M. Vannucchi Section of Hematology, University of Florence, Italy.
Efficacy, Hematologic Effects and Dose of Ruxolitinib in Myelofibrosis Patients with Low Platelet Starting Counts ( x 10 9 /L): A Comparison to Patients.
Changes in Quality of Life and Disease- Related Symptoms in Patients with Polycythemia Vera Receiving Ruxolitinib or Best Available Therapy: RESPONSE Trial.
Myeloproliferative Neoplasm (MPN) Clinical Trials Portfolio
Upfront Combination Therapy vs Step-Up Approach for PAH:
New Findings in Hematology: Independent Conference Coverage
CCO Independent Conference Highlights
Perspectives on Managing Polycythemia Vera for the Nurse Practitioner and Physician Assistant.
5-Azacytidine (AZA) in Combination with Ruxolitinib (RUX) as Therapy for Patients (pts) with Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPNs)1  
Verstovsek S et al. Proc ASH 2011;Abstract 793.
Harrison CN et al. Proc ASH 2015;Abstract 59.
Combination Ruxolitinib + Sonidegib in Myelofibrosis
PERSIST-1: Pacritinib Improved Spleen Volume Reductions in Myelofibrosis vs Best Available Therapy CCO Independent Conference Highlights of the 2015 ASCO.
New Findings in Hematology: Independent Conference Coverage
Burden of Atrial Fibrillation The Percentage of Strokes Attributable to AF Increases With Age.
How Many Inhibitors for JAK2?
Making Decisions With Your Osteoarthritis Patients
NOACs In Long-term VTE Treatment: A State Of The Art Review
Cardiogenic Shock.
Patient Presentation. Patient Presentation PRIMO Study Incidence of Muscle Adverse Effects.
UNDERSTANDING RISK STRATIFICATION IN PAH:
Pacritinib, a Dual JAK2/FLT3 Inhibitor: An Integrated Efficacy and Safety Analysis Of Phase II Trial Data In Patients With Primary and Secondary Myelofibrosis.
What Is New in HCM?.
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis.
SGLT2 Inhibitors in Phase 3 Trials
Treatment of Complicated Intra-abdominal Infections
CDK4/6 Inhibitors in Breast Cancer:
Advances in Myeloid Malignancies
A Focus on Polycythemia Vera for Nurse Practitioners and Physician Assistants.
HCV Protease Inhibitors in Clinical Practice
Is RA Treatment Addressing the Real Needs of Patients?
Learning Objectives Classification of VTE Goals of VTE Treatment.
Program Goals Overview Glatiramer Acetate 3 Times a Week.
Mutational Testing to Select Novel Targeted Therapies in AML
Translating the Latest and Greatest Advances in PAH Into Clinical Practice.
Managing Polycythemia Vera in the Community Setting
Future Directions in Myelofibrosis: Implications of Emerging Approaches.
Myeloid Updates From the Summer Congresses
Navigating Treatment Options in PAH
Pivotal Data Highlights on Myeloproliferative Neoplasms Myelofibrosis
What's New in Therapeutic Options for Moderate to Severe RA?
CMV in the HSCT Recipient
Prolonging the Effects of Factor IX Replacement Therapy in Hemophilia B.
Battling the Flu: Latest Advances in the Influenza Treatment Arsenal
Implications of Emerging Treatments for Beta-Thalassemia
HCV Protease Inhibitors in Clinical Practice
Evaluating BTK Inhibitors in CLL
Proteasome Inhibitors and Patients
JAK2 INHIBITORS AND ALLOGRAFTING
1 Verstovsek S et al. Proc ASH 2012;Abstract Cervantes F et al.
What Does the Future Hold and What Will It Mean for Patients?
Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I  Carole B. Miller, Rami S. Komrokji, Ruben A. Mesa,
Assessing the Burden of Hyperkalemia
An Unmet Need.
A Family Affair.
Tips on using ruxolitinib
Peanut Allergy Immunotherapy
Assessing the Burden of Hyperkalemia
VTE Treatment and Secondary Prevention VTE Treatment Trials Initial Dosing.
Treatment Advances for RA
Risk Stratification in MDS
Meet the JAKs.
Presentation transcript:

Addressing Unmet Needs in Myelofibrosis

Activity Goals

The MPN Burden: Treatment Goals

Risk Stratification Tools

Goals of Therapy: Individualizing Treatment

MPN Symptom Burden is Significant, and Worse Than General Population

COMFORT II: 5-Year Follow-up Duration of Spleen Response

Splenectomy

Ruxolitinib

Pacritinib-Induced Spleen Volume Reduction

Pacritinib vs BAT

Pacritinib-Induced Symptom Improvement

Pacritinib-Induced RBC Transfusion Independence

Momelotonib: JAK1/JAK2 Inhibitor

Imetelstat: First-in-Class Telomerase Inhibitor

Ruxolitinib Combinations ASH 2015

PRM-151 Adaptive Phase 2: Safety Through 36 Weeks

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.